GAO: 340B program netted savings and provided benefits for low-income patients
As pharma companies and industry groups seek limits on the 340B program, a new report from the GAO examined hospitals that received the pandemic’s eligibility exception and some of the savings generated for hospitals that participate in the program.
The 340B program requires pharma companies to sell outpatient drugs at discounted prices to covered entities, which include certain types of medical centers and hospitals, for the drugs to be covered by Medicaid. In addition to hospitals getting savings on the costs of those therapies, those providers can generate revenue when purchasing 340B drugs. Around 2,600 hospitals were participating in the program as of January.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
